- Home
- Media Center
- Press releases
- Financial
Financial
Johnson & Johnson Reports Q3 2021 Results
Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%* Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%* Company increasing 2021 Full-Year Guidance
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANTTM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer